Last CNY17.83 CNY
Change Today +0.04 / 0.22%
Volume 2.3M
300009 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 2:00 AM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

anhui anke biotechnology g-a (300009) Snapshot

Open
CNY17.80
Previous Close
CNY17.79
Day High
CNY17.98
Day Low
CNY17.56
52 Week High
10/16/14 - CNY19.62
52 Week Low
12/3/13 - CNY11.83
Market Cap
5.2B
Average Volume 10 Days
2.9M
EPS TTM
CNY0.37
Shares Outstanding
290.4M
EX-Date
06/6/14
P/E TM
48.7x
Dividend
CNY0.17
Dividend Yield
0.93%
Current Stock Chart for ANHUI ANKE BIOTECHNOLOGY G-A (300009)

Related News

No related news articles were found.

anhui anke biotechnology g-a (300009) Related Businessweek News

No Related Businessweek News Found

anhui anke biotechnology g-a (300009) Details

Anhui Anke Biotechnology (Group) Co., Ltd., together with its subsidiaries, develops, manufactures, and markets pharmaceuticals and health-care products in China and internationally. It offers recombinant human interferon alpha 2b for injection, interferon alpha 2b creams, interferon alpha 2b eye drops, and interferon alpha 2b suppository under the Anterferon name; and recombinant human growth hormone/somatropin for injection under the Ansomone name. The company also provides monoclonal antibody affinity gel to a-interferon; diagnostic kits; and adefovir dipivoxil tablets, an anti-virus medicine for oral administration. In addition, it offers traditional Chinese medicine and synthetic drugs, including dispersible tablets, adhesive plasters, oral liquids, ointments, granulation, capsules, tinctures, plasters, syrups, powders, and others. The company is based in Hefei, China.

anhui anke biotechnology g-a (300009) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

anhui anke biotechnology g-a (300009) Key Developments

Anhui Anke Biotechnology (Group) Co., Ltd. Announces Earnings Results for First Three Quarters of 2014

Anhui Anke Biotechnology (Group) Co., Ltd. announced earnings results for first three quarters of 2014. For the period, the company reported gross operating revenue of CNY 370.8484 million, rising 26.89% from a year earlier. Operating profit reached CNY 92.0153 million, hiking 23.8%. Net profit attributable to parent shareholders reached CNY 82.0889 million, jumping 26.44%. The figure deducting non-recurring profit and loss was CNY 79.3642 million, increasing 25.77%.

Anhui Anke Biotechnology (Group) Co., Ltd. to Report Q3, 2014 Results on Oct 22, 2014

Anhui Anke Biotechnology (Group) Co., Ltd. announced that they will report Q3, 2014 results on Oct 22, 2014

Anhui Anke Biotechnology (Group) Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 11, 2014

Anhui Anke Biotechnology (Group) Co., Ltd., Special/Extraordinary Shareholders Meeting, Sep 11, 2014., at 09:30 China Standard Time. Agenda: To consider by-election of independent directors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
300009:CH CNY17.83 CNY +0.04

300009 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 300009.
View Industry Companies
 

Industry Analysis

300009

Industry Average

Valuation 300009 Industry Range
Price/Earnings 48.8x
Price/Sales 10.2x
Price/Book 7.4x
Price/Cash Flow 48.4x
TEV/Sales 9.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANHUI ANKE BIOTECHNOLOGY G-A, please visit www.ankebio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.